• Info
  • Insider Trading

Insider Transactions Reported by 16 Insiders of Aktis Oncology, Inc.

Symbol
AKTS on Nasdaq
Location
Boston, MA

There are no Buy or Sell transactions made by insiders since 12 Mar 2025

Aktis Oncology, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Ansbert Gadicke 10%+ Owner $219,052,366 12 Jan 2026
MPM BIOVENTURES 2018, L.P. 10%+ Owner $219,052,366 12 Jan 2026
ELI LILLY & Co 10%+ Owner $135,446,834 12 Jan 2026
Todd Foley Director, 10%+ Owner $90,425,854 12 Jan 2026
Akos Czibere Chief Medical Officer 08 Jan 2026
Paul L. Feldman Chief Scientific Officer 08 Jan 2026
Shulamit Ron-Bigger Chief Operating Officer 08 Jan 2026
Matthew Roden President and CEO, Director 08 Jan 2026
Lloyd Mitchell Segal Director 12 Jan 2026
Ken Herrmann Director 08 Jan 2026
Helen Susan Kim Director, 10%+ Owner 12 Jan 2026
Kyle D. Kuvalanka Chief Financial Officer 08 Jan 2026
EcoR1 Capital, LLC Director 12 Jan 2026
Vida Ventures II, LLC 10%+ Owner 12 Jan 2026
Mary Thistle Director 08 Jan 2026
Michael A. Sherman Director 08 Jan 2026

Recent Insider Transactions by Companies or Individuals for Aktis Oncology, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Todd Foley AKTS Common Stock Purchase 5.82% 232,870 4,235,403 12 Jan 2026 See Footnote
Todd Foley AKTS Common Stock Conversion of derivative security 4,002,533 4,002,533 12 Jan 2026 See Footnote
Todd Foley AKTS Series B Redeemable Convertible Preferred Stock Conversion of derivative security -100% -2,727,273 0 12 Jan 2026 See Footnote
Todd Foley AKTS Series A Redeemable Convertible Preferred Stock Conversion of derivative security -100% -10,227,273 0 12 Jan 2026 See Footnote
Todd Foley AKTS Series Seed Redeemable Convertible Preferred Stock Conversion of derivative security -100% -2,272,727 0 12 Jan 2026 See Footnote
Mpm Bioventures 2018, L.P. AKTS Common Stock Purchase 12.2% 1,112,777 10,260,064 12 Jan 2026 See Footnote
Mpm Bioventures 2018, L.P. AKTS Common Stock Conversion of derivative security 2576.9% 8,805,578 9,147,287 12 Jan 2026 See Footnote
Mpm Bioventures 2018, L.P. AKTS Series B Redeemable Convertible Preferred Stock Conversion of derivative security -100% -6,000,000 0 12 Jan 2026 See Footnote
Mpm Bioventures 2018, L.P. AKTS Series A Redeemable Convertible Preferred Stock Conversion of derivative security -100% -22,500,000 0 12 Jan 2026 See Footnote
Mpm Bioventures 2018, L.P. AKTS Series Seed Redeemable Convertible Preferred Stock Conversion of derivative security -100% -5,000,000 0 12 Jan 2026 See Footnote
Ansbert Gadicke AKTS Common Stock Purchase 12.2% 1,112,777 10,260,064 12 Jan 2026 See Footnote
Ansbert Gadicke AKTS Common Stock Conversion of derivative security 2576.9% 8,805,578 9,147,287 12 Jan 2026 See Footnote
Ansbert Gadicke AKTS Series B Redeemable Convertible Preferred Stock Conversion of derivative security -100% -6,000,000 0 12 Jan 2026 See Footnote
Ansbert Gadicke AKTS Series A Redeemable Convertible Preferred Stock Conversion of derivative security -100% -22,500,000 0 12 Jan 2026 See Footnote
Ansbert Gadicke AKTS Series Seed Redeemable Convertible Preferred Stock Conversion of derivative security -100% -5,000,000 0 12 Jan 2026 See Footnote
EcoR1 Capital, LLC AKTS Common Stock Purchase 104.5% 2,222,222 4,348,658 12 Jan 2026 See Note
EcoR1 Capital, LLC AKTS Common Stock Conversion of derivative security 2,602,247 2,270,879 12 Jan 2026 See Note
EcoR1 Capital, LLC AKTS Class A Common Stock Conversion of derivative security 86,222 86,222 12 Jan 2026 See Note
EcoR1 Capital, LLC AKTS Class A Common Stock Conversion of derivative security 965,190 965,190 12 Jan 2026 See note
EcoR1 Capital, LLC AKTS Series B Redeemable Convertible Preferred Stock Conversion of derivative security -100% -2,500,000 0 12 Jan 2026 See note
EcoR1 Capital, LLC AKTS Series A Redeemable Convertible Preferred Stock Conversion of derivative security -100% -11,400,000 0 12 Jan 2026 See note
Vida Ventures II, LLC AKTS Common Stock Purchase 17.3% 835,000 5,671,825 12 Jan 2026 See Footnote
Vida Ventures II, LLC AKTS Common Stock Conversion of derivative security 4,994,212 4,859,370 12 Jan 2026 See Footnote
Vida Ventures II, LLC AKTS Series B Redeemable Convertible Preferred Stock Conversion of derivative security -100% -3,750,000 0 12 Jan 2026 See Footnote
Vida Ventures II, LLC AKTS Series A Redeemable Convertible Preferred Stock Conversion of derivative security -100% -15,250,000 0 12 Jan 2026 See Footnote
Helen Susan Kim AKTS Common Stock Purchase 17.3% 835,000 5,671,825 12 Jan 2026 See Footnote
Helen Susan Kim AKTS Common Stock Conversion of derivative security 4,994,212 4,859,370 12 Jan 2026 See Footnote
Helen Susan Kim AKTS Series B Redeemable Convertible Preferred Stock Conversion of derivative security -100% -3,750,000 0 12 Jan 2026 See Footnote
Helen Susan Kim AKTS Series A Redeemable Convertible Preferred Stock Conversion of derivative security -100% -15,250,000 0 12 Jan 2026 See Footnote
Lloyd Mitchell Segal AKTS Common Stock Conversion of derivative security 19,631 19,631 12 Jan 2026 See Footnote
Lloyd Mitchell Segal AKTS Series B Redeemable Convertible Preferred Stock Conversion of derivative security -100% -24,687 0 12 Jan 2026 See Footnote
Lloyd Mitchell Segal AKTS Series A Redeemable Convertible Preferred Stock Conversion of derivative security -100% -50,000 0 12 Jan 2026 See Footnote
* An asterisk sign (*) next to the price indicates that the price is likely invalid.